Itraconazole modulates hedgehog, WNT/β-catenin, as well as Akt signalling, and inhibits proliferation of cervical cancer cells
T Ueda, H Tsubamoto, K Inoue, K Sakata… - Anticancer …, 2017 - ar.iiarjournals.org
Background/Aim: Repurposing itraconazole as an anticancer agent has been evaluated in
several studies. The present study investigated whether itraconazole exerts an anticancer …
several studies. The present study investigated whether itraconazole exerts an anticancer …
Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non–small-cell lung cancer
SM Lee, R Rudd, PJ Woll, C Ottensmeier… - Journal of Clinical …, 2009 - ascopubs.org
Purpose Cancers rely on angiogenesis for their growth and dissemination. We hypothesized
that thalidomide, an oral antiangiogenic agent, when combined with chemotherapy, and as …
that thalidomide, an oral antiangiogenic agent, when combined with chemotherapy, and as …
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer
S Chatterjee, C Wieczorek, J Schöttle, M Siobal… - Cancer research, 2014 - AACR
Extensive oncologic experience argues that the most efficacious applications of
antiangiogenic agents rely upon a combination with cytotoxic drugs. Yet there remains a …
antiangiogenic agents rely upon a combination with cytotoxic drugs. Yet there remains a …
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night'
S Pilotto, M Bonomi, F Massari, M Milella… - Current …, 2014 - ingentaconnect.com
The discovery of specific molecular alterations (ie EGFR activating mutations, EML4/ALK
translocation, ROS1 rearrangements) in a selected population of patients affected by non …
translocation, ROS1 rearrangements) in a selected population of patients affected by non …
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in …
HT Tran, RG Zinner, GR Blumenschein Jr… - Investigational new …, 2011 - Springer
Purpose To assess the pharmacokinetics and evaluate potential drug-drug interactions
between erlotinib, paclitaxel and carboplatin. Experimental Design 1,079 previously …
between erlotinib, paclitaxel and carboplatin. Experimental Design 1,079 previously …
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid …
RA Graham, BL Lum, S Cheeti, JY Jin, K Jorga… - Clinical Cancer …, 2011 - AACR
Purpose: In a phase I trial for patients with refractory solid tumors, hedgehog pathway
inhibitor vismodegib (GDC-0449) showed little decline in plasma concentrations over 7 days …
inhibitor vismodegib (GDC-0449) showed little decline in plasma concentrations over 7 days …
Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?
M Ali, BA Telfer, C McCrudden, M O'Rourke… - Clinical cancer …, 2009 - AACR
Abstract Purpose: Poly (ADP-ribose) polymerase (PARP) plays an important role in DNA
repair, and PARP inhibitors can enhance the activity of DNA-damaging agents in vitro and in …
repair, and PARP inhibitors can enhance the activity of DNA-damaging agents in vitro and in …
Anti-fungal drug itraconazole exerts anti-cancer effects in oral squamous cell carcinoma via suppressing Hedgehog pathway
L Ban, T Mei, Q Su, W Li, Z Huang, L Liu, Y Wu, S Lv… - Life Sciences, 2020 - Elsevier
Aims To investigate the therapeutic potential of itraconazole in oral squamous cell
carcinoma (OSCC) and its molecular mechanism. Materials and methods The in vitro anti …
carcinoma (OSCC) and its molecular mechanism. Materials and methods The in vitro anti …
Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC): a meta-analysis of 7 randomized controlled trials
Background: This study aimed to assess the effectiveness and safety of angiogenesis
inhibitors for the treatment of patients with small cell lung cancer (SCLC) via meta-analysis …
inhibitors for the treatment of patients with small cell lung cancer (SCLC) via meta-analysis …
Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial
Background Cancer cells rely on angiogenesis for growth and dissemination, and small cell
lung cancer (SCLC) is a highly angiogenic tumor. We evaluated thalidomide, an anti …
lung cancer (SCLC) is a highly angiogenic tumor. We evaluated thalidomide, an anti …